5th January, 2021
– Destiny Pharma issued an announcement,
which is summarized as follows:
Phase 2b clinical
trial of XF-73 completes patient recruitment
Results expected in
Q1 2021
Destiny Pharma today announces that its XF-73 Phase 2b clinical trial was fully recruited by 31 December 2020, meeting the target timeline set for the programme.
Neil Clark, Chief
Executive Officer of Destiny Pharma, said: “We are very pleased to have
completed enrollment in our Phase 2b clinical trial testing XF-73 nasal gel as
a novel product preventing the incidence of post-surgical infections such as
MRSA. We previously reported excellent interim safety data in mid-2020 and are
now looking forward to announcing the full results of this study and planning
the Phase 3 clinical programme. There is a global need for better treatments to
prevent post-surgical infections in hospitals as recognized in the FastTrack
status awarded to XF-73 by the US FDA. There is also a significant commercial
opportunity for XF-73 in the hospital setting which we estimate could generate
peak annual product sales of $1 billion in the US alone.
The news today on our
XF-73 Phase 2b study is another major milestone for the Company and we continue
to look forward to announcing the study results in Q1 2021.”
Original website Link: